POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic ...

*Net of R&D tax credit. Poxel generated revenue of €2.183 million in the first half of 2025, compared to €1.162 million during the same period in 2024, corresponding mainly to ¥345 million in ...

Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and sales-based payments of up to $600 million ...

Poxel SA (POXEL) has delivered a 41.81% change over the past year, with a 52-week range between 0.17 and 0.83. What Is the Average Daily Trading Volume of Poxel SA (POXEL)? The average daily trading ...

Poxel has set out a new vision focused on midphase programs in rare metabolic diseases. The new strategy hits pause on plans to start a phase 2b nonalcoholic steatohepatitis (NASH) trial and makes no ...

As of 08:04 CEST. Market open. LYON, France, September 09, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments ...

Results from a phase 2 trial show PXL770 yielded consistently greater responses in high-risk patients with comorbid nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2D) compared with placebo.

LYON, France, May 16, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with ...

Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NASH), making it a potential first-to-market drug in the indication – ...